Roche-Partnered B7-H3 ADC Meets Phase 3 Endpoint in Small Cell Lung Cancer, Shows Competitive Safety Profile

As reported on Fierce BioTech, a phase 3 study conducted by MediLink has delivered positive results for Roche-partnered antibody-drug conjugate (ADC) tambotatug pelitecan (tam-peli), also known as YL201, in patients…

Continue Reading Roche-Partnered B7-H3 ADC Meets Phase 3 Endpoint in Small Cell Lung Cancer, Shows Competitive Safety Profile

Imfinzi–Imdelltra Combination Extends Survival in First-Line Extensive-Stage Small Cell Lung Cancer

As reported on PharmaBiz, a combination of Imfinzi (durvalumab) and Imdelltra (tarlatamab) has delivered significant improvements in survival outcomes for patients with extensive-stage small cell lung cancer (ES-SCLC), according to…

Continue Reading Imfinzi–Imdelltra Combination Extends Survival in First-Line Extensive-Stage Small Cell Lung Cancer
A Combination of Benmelstobart, Anlotinib, and Chemotherapy Improves Survival Rates in SCLC, Study Suggests
kalhh / Pixabay

A Combination of Benmelstobart, Anlotinib, and Chemotherapy Improves Survival Rates in SCLC, Study Suggests

  Advancing patient outcomes hinges on the development of targeted treatments, particularly in conditions with grim prognoses such as small cell lung cancer (SCLC), which typically has a life expectancy…

Continue Reading A Combination of Benmelstobart, Anlotinib, and Chemotherapy Improves Survival Rates in SCLC, Study Suggests
Experimental Therapies for Small Cell Lung Cancer and Acute Myeloid Leukemia Earn Orphan Drug Designation
source: pixabay.com

Experimental Therapies for Small Cell Lung Cancer and Acute Myeloid Leukemia Earn Orphan Drug Designation

According to a story from BioSpace, the biotechnology company Ascentage Pharma announced that two of its investigational treatments have recently received Orphan Drug designation from the US Food and Drug…

Continue Reading Experimental Therapies for Small Cell Lung Cancer and Acute Myeloid Leukemia Earn Orphan Drug Designation

Experimental Treatment For Small Cell Lung Cancer Receives Orphan Drug Designation

According to a story from pm360online.com, the drug development company Cytori Therapeutics recently announced that its investigational product ATI-1123 has been granted Orphan Drug designation from the US Food and…

Continue Reading Experimental Treatment For Small Cell Lung Cancer Receives Orphan Drug Designation